The mean versus the gene: will national healthcare systems ever adopt personalised medicine?

By John F P Bridges While outcomes for any given treatment differ significantly among patients, national healthcare systems continue to take a top down population perspective in reviewing not only epidemiologic data but to evaluating the effectiveness and cost-effectiveness of new medicines. This top down approach, coupled with a growing need for cost containment, has…

WHCC in Berlin: A glimpse into the future

By Ruth Whittington ([email protected]) The World Healthcare Congress, held March 10 – 13 in Berlin, always provides interesting insights on the ways governments, clinicians, and healthcare providers perceive healthcare delivery. In the same congress last year, held in Barcelona, two themes dominated the presentations and networking discussions. The first was the concept of an electronic…

The Pharmaceutical industry: Some good news to tell, but not always told well

By David Woods ([email protected]) The pharmaceutical industry is too often blamed for the stratospheric costs of healthcare — particularly in the United States. Yet, according to a series of surveys conducted by USA Today, the Kaiser Family Foundation, and the Harvard School of Public Health, pharmaceutical products account for only about 10% of the total…